Business Wire

ARTHUR-D.-LITTLE

27.6.2024 10:01:32 CEST | Business Wire | Press release

Share
New Arthur D. Little Blue Shift Institute Report Outlines 5 Scenarios for Future of Climate Change Adaptation

Whatever the success of climate change mitigation measures, companies and society will need to adapt to a changing world. To aid business climate change adaptation strategies, Arthur D. Little (ADL)’s Blue Shift Institute today published We’re doomed, now what?, an in-depth report that sets out five potential scenarios for adaptation and highlights relevant technologies to focus on.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240627698200/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Arthur D. Little Blue Shift Institute Report Outlines 5 Scenarios for Future of Climate Change Adaptation (Graphic: Business Wire)

The report is based on extensive analysis, interviews with over 40 international experts, surveys of business leaders, and was created in close collaboration with the United Nation’s (UN’s) World Intellectual Property Organization (WIPO).

It works on a “+3°C by 2100” outcome for climate change, based on projections by the Intergovernmental Panel on Climate Change (IPCC) and uses this to underpin five potential, non-exclusive scenarios for the future of climate change adaptation:

  • Green Communities: A resource-scarce world in which grassroots initiatives flourish, for lack of more ambitious projects; there is a pull towards greater decentralization, circularity, and frugality
  • Lonely at the top: Highly concentrated and competitive industries in which market leaders spearhead adaptation to build competitive advantage and keep satisfying consumers, while operating under increasing constraints
  • Wild Green West: A creative chaos in which private adaptation initiatives sprout everywhere, fueled by private capital and hype, with no overarching strategy or consistency
  • Don’t Look Up: A bleak future in which neither customers nor finance institutions have adjusted to the new climate reality, leaving nothing but quick fixes and crisis management
  • Adaptation Surge: A world in which adaptation is the norm and the new currency, resetting expectations, creating new markets and new needs for differentiation, and possibly overengineering

For each of these futures the report outlines the functional expectations and relevant technologies to drive adaptation. Alongside this, it includes “no regret” solutions, enabling technologies, and capabilities that will be vital, whatever the future brings, and that companies should invest in now.

Dr. Albert Meige, Global Director of Blue Shift at Arthur D. Little, comments: “When faced with prospective technology choices, executives often need to address three challenges: complexity, speed and cognition. Adaptation to climate change is no different. It is complex because climate impacts are local, multifactorial and highly variable; and also because there is a myriad of adaptation technologies available. By modeling potential scenarios we aim to cut through this complexity, providing CEOs with a clear guide to the potential technologies that their adaptation will require.”

Dr. Peter Oksen, Senior Program Officer at the World Intellectual Property Organization (WIPO) GREEN, comments: “This report offers a refreshing new angle to climate action, namely that of businesses and their priorities for adapting to a challenging future. It provides the scenario-based context for the technologies outlined by WIPO GREEN, underscoring the essential role of innovation in forging a sustainable future. By detailing the functional expectations and key technologies necessary for adaptation, it highlights the need to integrate technological advancements within our business, economic and policy frameworks to effectively combat climate change.”

We’re doomed, now what? can be accessed here: https://tinyurl.com/4w35xahm

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627698200/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye